Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Elevated Leverage ⢠Rich Valuation HAE shows strong liquidity and improving quarterly cash generation, but high leverage, intangible exposure, and elevated valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Rally losing momentum ⢠Holding key support ⢠Resistance remains firm Support Level: $101.95â$102.00 Resistance Level: $108.40â$108.80 HAE remains moderately bullish above $100 after last month's rally, but momentum is fading below $108.80 resistance, making $102 support and a reclaim of $108.80 key near-term triggers.
Sentiment & News
Key News Insights: ⢠Raised outlook ⢠Earnings growth ⢠Institutional buying Haemonetics' strong Q1 growth, raised FY2027 outlook, stock surge, and new institutional buying reinforce positive momentum despite ongoing international-revenue scrutiny.
AI Summary
HAE's shift toward diversified, higher-margin recurring consumables and MedSurg growth strengthens its long-term profile, but with shares near highs at ~40x earnings and meaningful debt, investors should wait for sustained free-cash-flow conversion and deleveragingâor a more attractive entryâbefore adding exposure.
Description
Haemonetics Corporation develops and sells medical devices and software for plasma collection, blood center operations, and hospital transfusion and hemostasis management. Its product set includes automated and manual collection systems, donor and blood bank information platforms, and perioperative hemostasis and cell-salvage equipment, marketed through a mix of direct sales, distributors, and representatives. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | HAE | Haemonetics Corporation | Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20. | Closed | -3.0% |